Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag ADR (OP:BAYRY)

14.28 +0.33 (+2.33%)

Streaming Delayed Price Updated: 1:09 PM EDT, Sep 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗

January 11, 2024

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the

Via Benzinga

Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial ↗

January 08, 2024

Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)

Via Benzinga

Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial ↗

January 04, 2024

Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.

Via Benzinga

Top Stocks, Sectors Loved By Congress Members Who Traded In 2023: Apple, NVIDIA, Microsoft, Ford And More Stocks To Watch In 2024 ↗

January 03, 2024

One of the hottest topics among members of Congress and investors has been the stock and options trading activity by several politicians.

Via Benzinga

Best 4 Agriculture Companies For Your 2024 Investment Portfolio ↗

December 27, 2023

Agriculture is and remains, a crucial sector for sustaining life, offering investors diverse opportunities in this vital industry.

Via Talk Markets

Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak ↗

December 26, 2023

In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin...

Via Benzinga

Topics Lawsuit

ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US ↗

December 19, 2023

With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience...

Via Benzinga

Topics Climate Change

AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗

December 16, 2023

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

Via InvestorPlace

Topics Artificial Intelligence

Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss ↗

December 06, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion ↗

December 04, 2023

The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts

Via Benzinga

Topics Lawsuit

PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out ↗

November 28, 2023

Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.

Via Benzinga

Topics Lawsuit

3 Battered Blue-Chip Stocks to Sell in December ↗

November 28, 2023

Steer clear of these once flourishing companies, each of which has problems they need to overcome before their share price rises again.

Via InvestorPlace

German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks ↗

November 24, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about...

Via Benzinga

Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence ↗

November 20, 2023

Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)

Via Benzinga

Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details ↗

November 20, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF)

Via Benzinga

Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits ↗

November 17, 2023

The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products...

Via Benzinga

Topics Lawsuit

Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss ↗

November 08, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced

Via Benzinga

Earnings Review: Bayer To Make Strategic Changes After Q3 Results ↗

November 08, 2023

The latest financial statements from Bayer Group show a year-over-year decline in several key areas, painting a stark picture of the company’s fiscal health.

Via Talk Markets

Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss ↗

November 01, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving ↗

September 27, 2023

Investors tend to closely watch which Cathie Wood stocks are bought and sold as she has history of generating big returns in her ETFs

Via InvestorPlace

AI To Revolutionize Clinical Trials And Diagnostics ↗

September 22, 2023

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...

Via Benzinga

Topics Artificial Intelligence

From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗

September 22, 2023

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...

Via Benzinga

Topics Artificial Intelligence

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch ↗

September 12, 2023

According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for...

Via Benzinga

Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗

August 28, 2023

Reuters

Via Benzinga

German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗

August 28, 2023

Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields...

Via Benzinga

FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗

August 21, 2023

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),

Via Benzinga

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? ↗

August 08, 2023

Tiziana Life Sciences, Inc.

Via Benzinga

Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema ↗

July 31, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,...

Via Benzinga

Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗

July 17, 2023

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in...

Via Benzinga

AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗

June 29, 2023

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.